Common-Size Income Statement
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Solvency Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Eli Lilly & Co., common-size consolidated income statement
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Operating income | The net result for the period of deducting operating expenses from operating revenues. | Eli Lilly & Co. operating income as a percentage of revenue decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |
| Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Eli Lilly & Co. income before income taxes as a percentage of revenue decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |
| Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Eli Lilly & Co. net income as a percentage of revenue decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |